{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:26:46Z","timestamp":1773124006874,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Dopamine replacement therapy is a cornerstone of Parkinson\u2019s disease treatment. In clinical practice, there is considerable variability in patients\u2019 responses, tolerability, and safety regarding anti-parkinsonian medications, which is largely influenced by genetic polymorphisms in pharmacokinetic and pharmacodynamic genes. However, the application of multigenetic pharmacogenomics-guided treatment (MPGT) to optimize therapeutic outcomes in Parkinson\u2019s disease (PD) remains under-explored. In this study, we conducted a prospective cohort investigation to evaluate the potential benefits of MPGT on motor symptoms in PD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 28 patients with PD were followed for 4 weeks. Among them, 22 patients underwent multigenetic pharmacogenomic testing, with 13 receiving treatments based on the test results (MPGT group). The remaining 15 received standard care (TAU group). Baseline characteristics, as well as changes in Unified Parkinson\u2019s Disease Rating Scale (UPDRS) III scores and sub-scores, were compared between the two groups. Associations between various single nucleotide polymorphisms (SNPs) and treatment outcomes were analyzed using generalized linear models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the 4-week follow-up, the MPGT group showed significantly greater reductions in UPDRS III total scores (p &amp;lt; 0.05) and limb sub-scores (p &amp;lt; 0.01) compared to the TAU group. These differences remained significant after adjusting for increases in levodopa equivalent daily dose (<jats:italic>p =<\/jats:italic> 0.011 and <jats:italic>p =<\/jats:italic> 0.002, respectively) and piribedil use (<jats:italic>p =<\/jats:italic> 0.006 and <jats:italic>p =<\/jats:italic> 0.004, respectively). Patients homozygous for the major allele of rs4984241 (AA vs. AG+GG, <jats:italic>p =<\/jats:italic> 0.003), rs4680 (GG vs. GA+AA, <jats:italic>p =<\/jats:italic> 0.013), rs1076560\/rs2283265 (CC vs. AC+AA, <jats:italic>p =<\/jats:italic> 0.039) and rs622342 (AA vs. AC, <jats:italic>p =<\/jats:italic> 0.043) showed greater improvement in total UPDRS III, postural instability and gait difficulty (PIGD), rigidity and tremor scores, respectively, compared to those carrying at least one minor allele.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MGPT demonstrates significant potential as a valuable tool for personalized treatment in PD patients. Additionally, we identified several SNPs associated with the responsiveness to chronic administration of multiple anti-parkinsonian drugs. However, to confirm these findings, well-designed studies with larger, well-characterized samples are necessary.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1502379","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:39:46Z","timestamp":1742938786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Multigenetic pharmacogenomics\u2013guided treatment shows greater improvements on motor symptoms compared to usual therapy in Parkinson\u2019s disease: a small real-word prospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yifan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengzhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongbao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1517\/17425255.2013.789018","article-title":"Anti-Parkinson's disease drugs and pharmacogenetic considerations","volume":"9","author":"Agundez","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/tpj.2014.85","article-title":"Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes","volume":"15","author":"Altar","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00228-009-0708-6","article-title":"Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson\u2019s disease","volume":"65","author":"Arbouw","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10048-010-0254-5","article-title":"OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users","volume":"12","author":"Becker","year":"2011","journal-title":"Neurogenetics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-0404.2004.00315.x","article-title":"The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson\u2019s disease","volume":"110","author":"Bialecka","year":"2004","journal-title":"Acta Neurol. Scand."},{"key":"B8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/FPC.0b013e328306c2f2","article-title":"The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications","volume":"18","author":"Bialecka","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000351097","article-title":"Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson\u2019s disease","volume":"13","author":"Cheshire","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ana.22155","article-title":"The COMT Val158Met polymorphism affects the response to entacapone in Parkinson\u2019s disease: a randomized crossover clinical trial","volume":"69","author":"Corvol","year":"2011","journal-title":"Ann. Neurol."},{"key":"B11","first-page":"226","article-title":"The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson\u2019s disease","volume":"22","author":"De La Fuente-Fernandez","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"106257","DOI":"10.1016\/j.clineuro.2020.106257","article-title":"Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson\u2019s disease","volume":"199","author":"Eryilmaz","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1006\/cbir.1997.0142","article-title":"Opossum kidney cells take up L-DOPA through an organic cation potential-dependent and proton-independent transporter","volume":"21","author":"Gomes","year":"1997","journal-title":"Cell Biol. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1124\/jpet.102.038885","article-title":"The cation transporters rOCT1 and rOCT2 interact with bicarbonate but play only a minor role for amantadine uptake into rat renal proximal tubules","volume":"303","author":"Goralski","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study","volume":"111","author":"Greden","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1124\/dmd.104.002519","article-title":"Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney","volume":"33","author":"Ishiguro","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.103.053298","article-title":"Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)","volume":"308","author":"Jonker","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2335518","DOI":"10.1001\/jamanetworkopen.2023.35518","article-title":"Multigenetic pharmacogenomics-guided treatment vs. treatment as usual among hospitalized men with schizophrenia: a randomized clinical trial","volume":"6","author":"Kang","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2217\/pgs.13.180","article-title":"Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects","volume":"14","author":"Kaniwa","year":"2013","journal-title":"Pharmacogenomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"520934","DOI":"10.3389\/fneur.2020.520934","article-title":"Polymorphism of the dopa-decarboxylase gene modifies the motor response to levodopa in Chinese patients with Parkinson\u2019s disease","volume":"11","author":"Li","year":"2020","journal-title":"Front. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00228-009-0658-z","article-title":"Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients","volume":"65","author":"Liu","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/brain\/aww109","article-title":"Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study","volume":"139","author":"Masellis","year":"2016","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2011.05.031","article-title":"Association of DRD2 and DRD3 polymorphisms with Parkinson\u2019s disease in a multiethnic consortium","volume":"307","author":"Mcguire","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e01537","DOI":"10.1002\/brb3.1537","article-title":"Gene polymorphisms and motor levodopa-induced complications in Parkinson\u2019s disease","volume":"10","author":"Michalowska","year":"2020","journal-title":"Brain Behav."},{"key":"B26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2017.12.010","article-title":"Dopaminergic polymorphisms associated with medication responsiveness of gait in Parkinson\u2019s disease","volume":"48","author":"Miller","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/FPC.0b013e3283441b95","article-title":"Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors","volume":"21","author":"Mirza","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/brain\/awv063","article-title":"Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson\u2019s disease","volume":"138","author":"Moreau","year":"2015","journal-title":"Brain"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.lfs.2007.01.035","article-title":"Blood-brain barrier transport of pramipexole, a dopamine D2 agonist","volume":"80","author":"Okura","year":"2007","journal-title":"Life Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/cts.12986","article-title":"Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: a randomized controlled trial","volume":"14","author":"Papastergiou","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B31","unstructured":"Parkinson disease-clinical annotations\n          \n          \n          2024"},{"key":"B32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/JGP.0b013e31815aff75","article-title":"Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly","volume":"16","author":"Pomara","year":"2008","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/sj.ki.5002020","article-title":"The role of carbonic anhydrases in renal physiology","volume":"71","author":"Purkerson","year":"2007","journal-title":"Kidney Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fphar.2019.00008","article-title":"Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson\u2019s disease","volume":"10","author":"Redensek","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/tpj.2016.79","article-title":"Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease","volume":"18","author":"Rieck","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1007\/s10072-021-05829-4","article-title":"Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"43","author":"Soraya","year":"2022","journal-title":"Neurol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jns.2016.08.005","article-title":"Association of the DRD2 CA(n)-STR and DRD3 Ser9Gly polymorphisms with Parkinson\u2019s disease and response to dopamine agonists","volume":"372","author":"Xu","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/00008571-200405000-00008","article-title":"A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity","volume":"14","author":"Yamanaka","year":"2004","journal-title":"Pharmacogenetics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1007\/s10072-021-05509-3","article-title":"Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson\u2019s disease-a meta-analysis","volume":"42","author":"Yin","year":"2021","journal-title":"Neurol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/gtmb.2020.0195","article-title":"Association of multiple dopamine D3 receptor gene 3\u2019UTR polymorphisms with susceptibility to Parkinson\u2019s disease and clinical efficacy of piribedil therapy","volume":"25","author":"Zhang","year":"2021","journal-title":"Genet. Test. Mol. Biomarkers"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1502379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:39:58Z","timestamp":1742938798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1502379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":40,"alternative-id":["10.3389\/fphar.2025.1502379"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1502379","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"article-number":"1502379"}}